November 10, 2017
A bipartisan deal is being reached in Congress to resolve an ongoing dispute over whether to let the Defense Department approve medical products in an emergency.
Under current law the FDA has the sole authority to make decisions on the use of medical products.
However, the Senate’s version of the 2018 National Defense Authorization Act would allow the Pentagon to sign off on unapproved drugs and medical devices.
The Department of Health and Human Services warned Congress the provision would undermine decades of FDA protections.
House and Senate lawmakers are meeting to work out the final version of the NDAA.